Product Description: Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C64H110N6O16
Citations: Department of Pharmaceutical Sciences. East Tennessee State University. 2015 May./Drug Metab Pharmacokinet. 2024 Mar 11, 101008./Toxicology Research and Application. September 25, 2018./Toxicology Research and Application. 2018, 2:239784731880115. /Department of Biological Science. National Sun Yat-Sen University. 2015 Sep./Front Biosci-Landmrk. 2023 Oct 17, 28(10), 238./Lipids Health Dis. 2018 Jul 31;17(1):183. /Neurobiol Dis. 2014 Nov;71:292-304.
References: [1]Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754-758/[2]Buczko W, et al. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008 Sep-Oct;60(5):623-31./[3]Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor.Biochem Biophys Res Commun, 2003, 308(4), 698-705./[4]Gradman AH, et al.Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 2005, 111(8), 1012-1018./[5]Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36(5):3014-3022. /[6]Ferri N, et al. Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):284-91.
CAS Number: 173334-58-2
Molecular Weight: 1219.59
Compound Purity: 99.80
Research Area: Cardiovascular Disease; Cancer
Solubility: H2O : ≥ 50 mg/mL
Target: Autophagy;Renin
English
Deutsch
